Items where authors include "Rea, D."

Article

Elder, K., Coles, C., Dodwell, D. et al. (23 more authors) (2025) SMALL: open surgery versus minimally invasive vacuum-assisted excision for small screen-detected breast cancer—protocol for a phase III randomised multicentre trial. BMJ Open, 15 (4). e099702. ISSN 2044-6055

Mellors, J. orcid.org/0000-0001-7761-8341, Dhaliwal, R., Longet, S. et al. (44 more authors) (2025) Complement-mediated enhancement of SARS-CoV-2 antibody neutralisation potency in vaccinated individuals. Nature Communications, 16 (1). 2666. ISSN 2041-1723

Colton, H. orcid.org/0000-0002-3287-4103, Barratt, N., Temperton, N. et al. (34 more authors) (2024) Greater preservation of SARS‐CoV‐2 neutralising antibody responses following the ChAdOx1‐S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients. British Journal of Haematology, 205 (6). pp. 2206-2218. ISSN 0007-1048

Group, F.C., Glasbey, J., Beggs, A. et al. (430 more authors) (2024) Risk of Bowel Obstruction in Patients Undergoing Neoadjuvant Chemotherapy for High-risk Colon Cancer. Annals of Surgery, 280 (2). pp. 283-293. ISSN 0003-4932

Goodyear, C.S., Patel, A., Barnes, E. et al. (118 more authors) (2024) Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial. The Lancet Rheumatology, 6 (6). e339-e351. ISSN 2665-9913

Goodyear, C.S., Patel, A., Barnes, E. et al. (119 more authors) (2024) Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial. The Lancet Rheumatology, 6 (6). e339-e351. ISSN 2665-9913

Barnes, E. orcid.org/0000-0002-0860-0831, Goodyear, C.S. orcid.org/0000-0001-5926-5941, Willicombe, M. orcid.org/0000-0002-6404-0584 et al. (154 more authors) (2023) SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease. Nature Medicine. ISSN 1078-8956

Barnes, E. orcid.org/0000-0002-0860-0831, Goodyear, C.S. orcid.org/0000-0001-5926-5941, Willicombe, M. orcid.org/0000-0002-6404-0584 et al. (154 more authors) (2023) SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease. Nature Medicine, 29 (7). pp. 1760-1774. ISSN 1078-8956

Bergamino, M.A. orcid.org/0000-0002-1091-2711, López-Knowles, E. orcid.org/0000-0002-0893-3361, Morani, G. orcid.org/0000-0002-6385-3137 et al. (173 more authors) (2022) HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer. eBioMedicine, 83. 104205. ISSN 2352-3964

Robertson, J.F.R., Coleman, R.E. orcid.org/0000-0002-4275-1043, Cheung, K.-L. et al. (21 more authors) (2020) Proliferation and AKT activity biomarker analyses after capivasertib (AZD5363) treatment of patients with ER+ invasive breast cancer (STAKT). Clinical Cancer Research, 26 (7). pp. 1574-1585. ISSN 1078-0432